P/B
—
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
$236.6M
Market Cap • 10/9/2026
2015
(11 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
56,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
236,6M
EV
152,6M
EV/Revenue
36,2
EV/EBITDA
-3
EV/EBIT
-2,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-25,9%
Total Yield
-25,9%
Payout
0%
Retained Earnings
-344M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
917,7%
Capex/Revenue
3,1%
Capex/D&A
7,1%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
2,7%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,6
Debt/Equity
0%
Current Ratio
4,7
Quick Ratio
4,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!